Tag Archives: cardiology

Elder Pharma Reaffirms Commitment to Clear All Dues by Raising Funds Through Asset Sale or Debt or Issue of Equity

* Revival in business operations likely to relieve Cash flow issues in the long term.

Mumbai, India, November 12th, 2015 — Elder Pharmaceuticals Ltd (NSE: ELDERPHARM) is committed to repaying all its creditors (secured and unsecured) by raising funds through a combination of debt, equity and asset sale. The company has already informed the exchanges regarding its intention of selling its stake in its subsidiaries in UK and Bulgaria. The company has been going through tough cash flow situations but is on the path of recovery and has substantial asset base to cover all its liabilities. Raising funds is a time consuming process and cannot be done overnight as the ‘due-diligence’ by lenders/investors takes up many months at times.

However, in recent times the company has been faced with a number of litigations – many of which are motivated – which are in effect further delaying the company’s recovery or plans to sell assets. Due to these numerous legal issues – coupled with a slow real estate market – the company has not been able to sell off its non- core assets quickly or at the right price. But the efforts continue to realize the best value for the non-core assets.

The company has also been facing a lot of negative publicity in the media, most of which is completely false, derogatory and defamatory and liable for libel. In spite of the motivated campaign to systematically tarnish its image the company enjoys a strong goodwill in market which is enabling it to revive and increase its business operations slowly but steadily. Once the company’s profitable business model reaches its earlier stage it will have sufficient cash flows to take care of its various financial needs. The only thing coming in the way are the multitude cases filed against the company.

The company and its promoters remain committed to doing their best to repay all the liabilities and to turn around the business. This commitment is not only to the investors, creditors and depositors, but also to the more than 1000 families who still believe in the Elder dream.

Elder is a major player in the anti-infectives, multi-vitamins, cardiology and skincare segments apart from the OTC segment. Although the company has sold off its 30 brands to Torrent more than a year back – it still has the international rights for these brands including Shelcal, its leading calcium supplement brand. Elder Pharma has already started exports of these brands to about 25 countries with many more on the anvil. With overwhelming response and acceptance of its product globally, the company is looking at strong prescription base in over 70 countries by March 2017. Another fast growing product is Eldervit, a prescription drug which acts as a vitamin & minerals supplement to boost energy. In addition to injection form, Elder has started making Eldervit available in capsules, gel capsules and sachet forms to make it acceptable to all age groups. The company is a market leader in wound healing and injectable B12 vitamin.

Press & Media Contact:
Mitesh M Kapadia
Sentinel Public Relations Pvt Ltd / Sentinel Advertising Services
B-603, Samajdeep, Near Bhanu Park/Seasons Restaurant
Adukia Road, Off S V Road
Kandivli (W), Mumbai 400 067 India
Mob: +91 98205 03876
Tel: (022) 28625131/32
Fax: (022) 28625133
mitesh@publicrelationindia.com
http://www.publicrelationindia.com
http://www.elderindia.com

Elder Pharmaceuticals Clears Pending Statutory Payments Related to TDS, PF, ESIC, MWLF etc After Witnessing Turnaround in Cash Flow Position

Elder Pharmaceuticals Limited which was going through an erratic cash flow situation has made major pending statutory payments of TDS, provident fund, ESIC, Maharashtra Labour Welfare Fund (MLWF) etc to the tune of approx Rs 26 crore.

Mumbai, India, March 25th, 2015 — Elder Pharmaceuticals Limited (BSE: 532322 | NSE: ELDERPHARMEQ) which was going through an erratic cash flow situation has made major pending statutory payments of TDS, provident fund, ESIC, Maharashtra Labour Welfare Fund (MLWF) etc to the tune of approx Rs 26 crore. The company has informed the BSE & NSE to this effect.

http://www.bseindia.com/corporates/anndet_new.aspx?newsid=d6c05454-0734-4f82-b876-348077f1f915

Elder Pharmaceuticals plans to clear the backlog of other payments very soon. Elder is also in talks to raise fresh funds through a combination of debt or debt cum equity in order to improve its cash flow and performance. The company’s cash flow cycle was affected for a larger part of FY 2014-15 resulting in payments getting delayed to its various creditors and government bodies. In view of the growth in sales of its pharma & OTC products recently, the company is anticipating regular cash infusion which will contribute to its working capital, regular expenses and debt retirement needs.

Elder Pharmaceuticals is a major player in the Anti-infectives, Multi Vitamins, Cardiology and Skin care segments and is also present in the Over The Counter segment (OTC) through its products like AM/PM, Solo, Respite, Rhyme covering sectors like Oral Mouthwash, Skin Care, Nasal Decongestion, Muscle relaxants and Color Cosmetics. Elder has a prominent position in the pharma space in India and abroad with its products commanding good demand from hospitals, doctors etc. A few products like Eldervit (a nutraceutical), anti-infectives like Cefixime based Formic and Elfi, & Skin O2 (dermatology) have significant market share and are growing at over 14% annually. The company has 6 state-of-the-art production facilities across India backed by a team of over 2 dozen scientists.

Going forward, the company is embarking on a major price revamp supported by an aggressive national expansion campaign in order to garner a larger share in the domestic market. Elder’s International operations are registering steady growth and more than 40% of Elder’s revenue is likely to come from its global business. As a part of Elder’s deal with Torrent Pharmaceuticals in 2013 – which involved sale of over 30 brands and transfer of Elder’s domestic employees to Torrent – Elder shall utilize its six plants for contract manufacture of the formulations business sold to Torrent for 3 years which will fetch Elder a continous revenue stream of Rs 70 – 75 crore every year.

Elder group is targeting a turnover of about Rs 1000 cr from its domestic and international operations by FY 2017.

Press & Media Contact:
Mitesh M Kapadia
Sentinel Public Relations Pvt Ltd / Sentinel Advertising Services
B-603, Samajdeep, Near Bhanu Park/Seasons Restaurant
Adukia Road, Off S V Road
Kandivli (W), Mumbai 400 067 India
Mob: +91 98205 03876
Tel: (022) 28625131/32
Fax: (022) 28625133
mitesh@publicrelationindia.com
http://www.publicrelationindia.com
http://www.elderindia.com

Englewood Hospital and Medical Center Ranked Nationally For Medical Excellence and Patient Safety

Englewood, NJ, November 9, 2011 – Englewood Hospital and Medical Center has earned national recognition again for its delivery of outstanding medical care according to the 2012 CareChex? release of America’s Top Quality Hospitals. The Medical Center has earned top national and state rankings in the Medical Excellence and the Patient Safety categories:

Top 100 in the Nation for Medical Excellence
– Heart Attack Treatment
– Interventional Carotid Care

Top 10% in Nation for Medical Excellence:
– Cardiac Care
– General Surgery
– Heart Attack Treatment
– Interventional Carotid Care

Top 10% in Nation for Patient Safety
– Gastrointestinal Care
– Gastrointestinal Hemorrhage
– Heart Attack Treatment
– Heart Failure Treatment
– Hip Fracture Repair
– Neurological Care
– Overall Medical Care
– Stroke Care

“CareChex allows the public to make informed decisions regarding the quality of medical care provided by hospitals,” said Dr. Thane Forthman, managing principal at The Delta Group. “We are pleased to acknowledge that Englewood Hospital has achieved an exceptionally high level of performance across all components of medical quality. Englewood Hospital is a benchmark that other hospitals should seek to emulate.”

CareChex? is a hospital quality rating service of The Delta Group, a national healthcare information services company that provides clinical, financial, and patient satisfaction findings to consumers, providers, and purchasers of U.S. medical care. Unlike other publicly available hospital quality ratings, CareChex provides a comprehensive evaluation of all components of medical quality including process of care, outcomes of care, and patient satisfaction.

“This significant recognition from CareChex is indicative of Englewood Hospital’s commitment to the delivery of safe and outstanding care and clinical outcomes for our patients,” said Douglas Duchak, President and CEO of Englewood Hospital and Medical Center. “We are honored to be recognized again by CareChex and we look forward to providing our patients with continued access to quality medical services.”

About The Delta Group:
The Delta Group is a leading healthcare information services and consulting company dedicated to providing an extensive array of products and services designed to measure, manage, and monitor the clinical, financial, and market performance of healthcare organizations.

About Englewood Hospital and Medical Center:
Englewood Hospital and Medical Center provides the highest level of compassionate, patient care and safety through a broad range of advanced clinical programs, treatments and diagnostic services. It is renowned for its bloodless medicine and surgery program, cardiac and vascular programs and its leadership in breast care, oncology and joint replacement services. Through its affiliation with the Mount Sinai School of Medicine and the Mount Sinai Consortium for Graduate Medical Education, this acute-care and community teaching hospital trains medical residents in many disciplines, including internal medicine, critical care medicine, surgery, pediatrics, podiatry, and pathology. Its Vascular Fellowship Program has trained a generation of world-class vascular surgeons. Additionally, many members of Englewood Hospital’s medical staff serve as faculty at Mount Sinai. Englewood Hospital has earned numerous awards and accreditations from the Joint Commission, J.D. Power and Associates, HealthGrades, and other organizations. Englewood Hospital is among the six percent of hospitals nationwide honored by the American Nurses Credentialing Center with the prestigious MagnetT status, the highest recognition for nursing excellence – a distinction earned three consecutive times by our nursing staff.

Maria Margiotta
Director, Marketing and Communications
Englewood Hospital and Medical Center
350 Engle Street – 1st Floor, North Annex
Englewood, NJ 07631
Direct. 201-894-3524 | Fax. 201-569-6126
http://www.bestheartdocs.com